Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Featured trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

  • 2446 views
  • 23 Nov, 2020
  • 18 locations
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent (SOLSTICE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.

tumor necrosis factor
polyarticular arthritis
spondylitis
psoriasis
tumor necrosis factor alpha
  • 0 views
  • 20 Sep, 2022
  • 89 locations
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with vedolizumab. Remission …

tumour necrosis
remission
proctitis
pancolitis
vedolizumab
  • 0 views
  • 19 Sep, 2022
  • 62 locations
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)

prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.

etanercept
infliximab
golimumab
tumor necrosis factor
polyarticular arthritis
  • 7 views
  • 25 Jul, 2022
  • 16 locations
Radiofrequency Perineural Injection Idiopathic Carpal Tunnel Syndrome

procedure, one week ,two month and four months after procedure except SNCV and serum CRP and TNF (tumor necrosis factor alpha)will be done before the procedure and after four months only):

tingling sensation
Accepts healthy volunteers
bupivacaine
conservative management
paresthesia
  • 1 views
  • 06 Oct, 2021
  • 1 location
Topical Infliximab for Sterile Corneal Melt

necrolysis or mucous membrane pemphigoid. Infliximab is an antibody against tumour necrosis factor alpha and has been used to treat or prevent corneal melt in certain patients with inflammatory of

  • 11 views
  • 24 Feb, 2022
  • 1 location
Low Level Tragus Stimulation in Acute Decompensated Heart Failure (TREAT-HF)

of cytokines such as C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10) and Tumor Necrosis Factor alpha (TNFα) in patients with heart failure (HF). Increased

cytokines
vagal stimulation
acute heart failure
  • 0 views
  • 23 Feb, 2022
  • 1 location
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind Multi-centre Trial (RAPID-I) (RAPID-I)

This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a …

amylase
acute pancreatitis
abdominal pain
  • 7 views
  • 11 Mar, 2022
  • 1 location
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16 in subjects with …

NSAID
x-rays
  • 4 views
  • 05 Apr, 2022
An Explorative Psoriasis Biomarker Study

Plaque psoriasis may be an ideal model disease to explore potential therapeutic effects of immunosuppressive agents, given the easy accessibility of inflammatory lesions. In this study, the applicability of a systems dermatology approach is investigated in order to better assess the efficacy of psoriasis treatments at an early clinical stage. …

  • 0 views
  • 24 Jun, 2021
  • 1 location